Laboratório de Tecnologia e Biotecnologia Farmacêutica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59010-115, Brazil.
Programa de Pós-Graduação em Bioquímica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte 59072-970, Brazil.
Toxins (Basel). 2018 Apr 18;10(4):161. doi: 10.3390/toxins10040161.
Scorpion venom is a rich source of biologically active components and various peptides with high-potential therapeutic use that have been characterized for their antimicrobial and antiproliferative activities. Stigmurin is a peptide identified from the venom gland with high antibacterial and antiproliferative activities and low toxicity. Amino acid substitutions in peptides without a disulfide bridge sequence have been made with the aim of reducing their toxicity and increasing their biological activities. The purpose of this study was to evaluate the structural conformation and structural stability, as well as antimicrobial, antiproliferative, and hemolytic activities of two peptide analogs to Stigmurin, denominated StigA6 and StigA16. In silico analysis revealed the α-helix structure for both analog peptides, which was confirmed by circular dichroism. Data showed that the net charge and hydrophobic moment of the analog peptides were higher than those for Stigmurin, which can explain the increase in antimicrobial activity presented by them. Both analog peptides exhibited activity on cancerous cells similar to the native peptide; however, they were less toxic when tested on the normal cell line. These results reveal a potential biotechnological application of the analog peptides StigA6 and StigA16 as prototypes to new therapeutic agents.
蝎毒是生物活性成分和具有高潜力治疗用途的各种肽的丰富来源,其具有抗菌和抗增殖活性已得到表征。Stigmurin 是一种从毒液腺中鉴定出的具有高抗菌和抗增殖活性且毒性低的肽。对没有二硫键序列的肽进行氨基酸取代,目的是降低其毒性并提高其生物活性。本研究旨在评估两种 Stigmurin 肽类似物(命名为 StigA6 和 StigA16)的结构构象和结构稳定性,以及抗菌、抗增殖和溶血活性。计算机分析显示两种类似肽均具有α-螺旋结构,这通过圆二色性得到证实。数据表明,类似肽的净电荷和疏水性矩均高于 Stigmurin,这可以解释它们表现出的抗菌活性增加。两种类似肽对癌细胞的活性与天然肽相似,但在正常细胞系上测试时毒性较低。这些结果揭示了类似肽 StigA6 和 StigA16 作为新型治疗剂原型的潜在生物技术应用。